Ariel Porat is the Alain Poher Professor of Law, and the president of  Tel Aviv University (2019-present). He is a member of the Israel Academy of Sciences and the EMET Prize Laureate (2014). In 2002-2006, he was the Dean of Tel Aviv University Faculty of Law.

From 2003 until his appointment as the president of the university, he was also an Associate Member and Fischel-Neil Distinguished Visiting Professor of Law at the University of Chicago. In addition, he was a Visiting Professor at the Universities of Berkeley, Columbia, New York, Stanford, Toronto and Virginia.

He is a member of the American Law Institute, a former board member of the American Law and Economics Association and a former president of the Israeli Law and Economics Association. From 1997-2002, he was the Director of the Cegla Center for Interdisciplinary Research of the Law.

He is the founder of the journal Theoretical Inquiries in Law and was its editor in chief in the years 1999-2003. He is the author of several books including Tort Liability under Uncertainty (Oxford University Press, 2001) (with Alex Stein), Getting Incentives Right (Princeton University Press, 2014) (with Robert Cooter) and Personalized Law: Different Rules for Different People (Oxford University Press, 2021) (with Omri Ben-Shahar).

He also authored numerous articles mainly in torts and contracts, most recently “The Restoration Remedy in Private Law” 119 Columbia Law Review 1901 (2018) (with Omri Ben-Shahar); “Limited Inalienability Rules,” 107 Georgetown Law Journal 701 (2019) (with Stephen Sugarman); “Personalizing Mandatory Rules in Contract Law” 86 University of Chicago Law Review 255 (2019) (with Omri Ben-Shahar); “Free Speech and Cheap Talk” 11 Journal of Legal Analysis 46 (2019) (with Daniel Hemel), “Disclosures Rules in Contract Law” 49 Journal of Legal Studies 103 (2020) (with O. Bar-Gill) and “Tort Liability and the Risk of Discriminatory Government” 87 University of Chicago Law Review 1 (2020) (with Ehud Guttel).

Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is the Director of a national nanomedicine initiative project. Prof. Peer is the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals.

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in Cancer and inflammation. In addition, his lab was the first to show systemic, cell specific delivery of mRNA molecules.

Peer Peer and his team have done innovative and groundbreaking work in cancer, mostly in brain tumors (Glioblastoma), Ovarian Cancer, and a set of blood cancers (Mantle Cell Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia) and in inflammaotry bowel diseases.

His work is published in premier scientific journals and he is the editor and author of several books in the field of nanomedicine. In addition, he is an associate editor of Journal of Controlled Release, and a member of the editorial boards of numerous journals including Cancer Letters and ACS Bioconjugate Chemistry.  He has received more than 30 awards; among them, he was recognized by the Kenneth Rainin Foundation by their Innovator (2010) and Breakthrough (2011 – 2013) Awards for his pioneering work in inflammatory bowel diseases and by the AAAS and the Untold news breakthrough Award for his development of the Gagomers platform for cancer targeted drug delivery. In 2017, he received the  2017 Nanos Award for major contribution to the field of clinical nanomedicine in CLINAM 10^th, Basal, Switzerland.

Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, five spin-off companies were generated aiming to bring personalized medicine into clinical practice.

Prof. Peer is a past President of the Israeli Chapter of the Controlled Release Society, and a Member of the Israel Young Academy of Sciences.

Director-General of Tel Aviv University

Gady Frank is an alumnus of Tel Aviv University, having completed both his BA degree in Economics (Cum Laude) and Communication and MA in Economics (Cum Laude) at the University. From 2006-09 Mr. Frank served as senior economist on the National Economic Council of the Prime Minister’s Office. He then went on to hold several key positions on the Planning and Budgeting Committee of the Council for Higher Education (CHE), including serving as Deputy Director-General for Planning and Policy from 2009-11; Deputy Director General, Head of Budgeting Division from 2011-13; and Director General of the Planning and Budgetary Committee and the CHE from 2013-2017.

Prof. Benhar received his PhD in Molecular Biology from Hebrew University in 1992, where he studied control of bacterial gene expression. Prof. Benhar did his post-doctoral training at the National Cancer Institute, NIH, working with Dr. Ira Pastan on recombinant immunotoxins.  In 1995, Prof. Benhar joined the Department of Molecular Microbiology and Biotechnology at Tel Aviv University as a tenure-track assistant professor. Prof. Benhar received tenure in 2002, became an associate professor in 2005 and a full professor in 2008.  Between 2007 to 2011 Prof. Benhar served as the Department Chairman. Since 2014, Prof. Benhar is serving as Vice Dean for Research of the Faculty of Life Sciences.

CEO at Ramot

Ronen Kreizman is responsible for the management and commercial development of all technologies and intellectual property arising from Tel Aviv University research and innovation initiatives. This includes industry liaison, IP management, business development, technology commercialization, and the formation of startup companies and new ventures around TAU technologies. He also plays a key role in creating collaborations with industry leaders and initiating funded research projects for TAU faculty.

Ronen has extensive experience in startups, business development and technology licensing, having previously served as General Manager of WIN, the startup hub of the Weizmann innovation ecosystem, where he managed the end-to-end venture creation process. His prior role as VP Business Development Life Sciences at Yeda, the technology transfer company of the Weizmann Institute of Science, involved overseeing the commercial pipeline and dealmaking activities across the entire life sciences field, including pharmaceuticals, biotechnology, agrotech, and foodtech. In this capacity, he led a team of business development directors and managed Yeda’s strategic partnerships and commercial deals. Prior to that Ronen served as a Senior Director Business Development in Yeda’s Exact Sciences area, and Head of Corporate Strategy.

Before joining Yeda, Ronen was a Senior Management Consultant with Deloitte, where he led challenging projects related to corporate strategy, growth strategy, go-to-market plans, and commercial due diligence for global and local companies and governmental organizations. His experience spans various fields and industries. Prior to that Ronen was head of R&D in a spinoff company of the Weizmann Institute.

Ronen holds a Ph.D. in Materials Science from the Weizmann Institute of Science. He earned his B.Sc. and M.Sc. degrees in Materials Engineering from Ben-Gurion University of the Negev.

Ronen has been involved in the formation and oversight of numerous startups, serving as a board observer and member in various companies, including Phytolon, ProFuse Technology, FreezeM and AIONZ.

Dr. Kinneret Livnat Savitzky is the Director / Chairperson at a variety of biotech entities, and Held director / chairperson position in a number of companies and organizations including BioLineRx, ILSI, Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), Compugen Ltd., KAHR medical, DreaMed Diabetes, Biomica, Hadasit, FutuRx and its portfolio companies.

She is also serving as the Chief Executive Officer and Board member of FutuRx, an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation and Takeda Ventures Inc., with the office of the Israeli Innovation Authority (IIA). Recently Bayer’s venture arm LEAPS joined as a partner in FutuRx as well.

Before that she served as Chief Executive Officer of BioLineRx, General Manager of Bioline Innovations Jerusalem (BIJ) Between the years 2005 – 2009, VP of drug development, BiolineRx Between 2004 – 2005.

Between the years 1997 – 2004 Dr. Savitzky held several positions, the last of which being Vice President of Biology at Compugen Ltd. Besides the Biology R&D, was involved in collaborations with global pharmaceutical companies.

Dr. Savitzky holds the titles: Ph.D. with distinction in Human Genetics from Tel Aviv University, Master’s degree in human genetics from Tel Aviv University and B.Sc. in Biology from The Hebrew University of Jerusalem.

Dr. Margolin has more than 35 years of experience in the biotech, pharmaceutical and venture capital industries.

Served as President and CEO of Gamida Cell between 2005-2018, leading the company from preclinical development through phase 3 international registration studies. Former Vice President of Denali Ventures LLS, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a Ph.D. in Biology from the Weizmann Institute of Science and was a post-doctoral associate at the Yael University School of Medicine.

Dr. Yuval Cabilly is co-founder and Managing Partner of Israel Biotech Fund, a venture capital fund investing in exceptional Israeli pharmaceutical companies.

Dr. Cabilly serves on the Board of Directors of Pharma Two B and Tamarix. He is also co-founder and Board Member of 8400 – The Health Network.

Dr. Cabilly received his PhD in molecular cell biology from the Tel Aviv University. His research focused on neurodegenerative diseases.

Imad Telhami is a Businessman and entrepreneur who has substantial management experience and a long and successful history in global management.
For 25 Years he served in various management positions of Delta Galil and as a CEO.

In 2008, Telhami founded Babcom Centers in north. In 2020 the company employed approximately 3000 employees, of which 70% are from the Arab sector and 80% women. Babcom has sites all across the country. Babcom focuses on two main objectives: investing in people and providing excellent, high quality services including call centers, software and other services.
In line with Telhami’s vision, the company has Arab and Jewish stakeholders and was co-founded with the industrialist, Dov Lautman.
Telhami is committed to empowering and advancing the Arab community in Israel.
Telhami has served in positions on several councils and boards of directors and has participated in a number of projects with partners who share his commitment, including:
The Lautman Fund, Appleseeds Academy, member of the Board and Executive Committee of the University of Haifa.

He is a member of the Board of Kav Mashve ,Alfanar, the Israel democracy institute.
Telhami founded in 2014 Takwin Labs, an investment fund for Arab entrepreneurs together with Chemi Peres and Erel Margalit. The fund made 8 investments and following its success it is now raising a follow up fund, Takwin Ventures 2.

In 2010 The Marker magazine chose Mr. Telhami as one of the 101 influencers for the benefit of Israeli society and economy.

In 2018 he received a PhD degree in honor of his work for integrating social work in his business on behalf of the Ben Gurion university.

In 2018 Harvard business school build a CASE STUDY about Babcom and the leadership of Telhami about the unique model of multicultural company and doing business with compaction. The case study became part of the curriculum in HBS.

In 2019 he received the Hugo Ramniceanu Economic award from the Tel Aviv University.
The Hugo Ramniceanu economy award was given in recognition of achievements in economics technology research and development in Israel.

Dr. Sheinin is an expert in the Israeli economy with over 30 years of experience. She specializes in building macroeconomic models for forecasting, economic analyses and simulations, particularly for the business sector. Her parallel line of expertise is investment management.

She is a cofounder of Economic Models Ltd, one of Israel’s foremost macroeconomic research, forecasting and economic consulting firms that served many of the largest and most significant business companies in the Israeli economy. Rachel focused on linking the macro forecasts to the specific products and services of clients.
Rachel is also a cofounder of Capital Market Models, an investment house for management of financial assets, and of Mutual Funds Models, a mutual fund management company, specializing in government and corporate bonds (in Israel and the USA).
Since 2016, Dr. Sheinin has served as Chairperson of the Investment Committee for Mutual Funds Models Ltd. and is currently the CEO of Capital Markets Models and Executive Vice President of Economic Models Ltd. She has lectured on various aspects of economics at various academic institutions.

From 2011-2019, Rachel served as a member of the Appointment Review Committee, an independent acting under the authority of the Government Companies Law.
Since 2005, Dr. Sheinin has served as a member of the Board of Trustees of the Pinhas Sapir Center for Development at Tel Aviv University.
Dr. Sheinin has a Ph.D. & MA in economics from Tel Aviv University, and a BA in art history & economics from Tel Aviv University.

Prof. Hagit Messer-Yaron received the Ph.D. in Electrical Engineering from Tel Aviv University (TAU), ISRAEL, and after a post-doctoral fellowship at Yale University, she joined the faculty of Engineering at Tel Aviv University in 1986, where she is The Kranzberg Chair Professor in Signal Processing at the school of Electrical Engineering.

On 2000-3 she has been on leave from TAU, serving as the Chief Scientist at the Ministry of Science. After returning to TAU she was the head of the Porter school of environmental studies (2004-6), and the Vice President for Research and Development (2006-8).  Then, she has been the President of the Open University (2008-13), and from Oct. 2013 till January 2016 she has served as the Vice Chair of the Council of Higher Education, Israel. She was also one of the co-founders of ClimaCell.

Prof. Messer-Yaron, a Life Fellow of the IEEE, is an active researcher in the field of Statistical Signal Processing, with applications to environmental monitoring. She is also interested in various aspects of higher education and science policy, including science-society interplay, women in science and technology, and commercialization of academic research. Prof. Messer-Yaron is a member of COMEST, UNESCO committee for ethics in Science and Technology, and a member of the Executive Committee of the IEEE Global Initiative for Ethical Considerations in Artificial Intelligence and Autonomous Systems.